{"entity":{"id":"nct07098988","kind":"trial","name":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","aka":[],"tldr":"A phase 2 trial of Visugromab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by CatalYm GmbH, now recruiting.","summary":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC is a phase 2 interventional study registered as NCT07098988 by CatalYm GmbH, with 107 participants planned, started 2025-08-01 and due to reach its primary completion in 2029-03-31. Interventions recorded: Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2, Carboplatin AUC 5. Conditions listed: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07098988","url":"https://clinicaltrials.gov/study/NCT07098988"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["visugromab","pembrolizumab"],"companies":["catalym"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07098988","phase":"2","setting":"A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)","sponsor":"CatalYm GmbH","enrolled":107,"outcomes":[]},"route":"/trials/nct07098988/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"visugromab","kind":"drug","name":"Visugromab","route":"/drugs/visugromab/"}],"company":[{"id":"catalym","kind":"company","name":"CatalYm","route":"/companies/catalym/"}]}}